Lonza Group Ltd - Company Profile
Powered by 
All the data and insights you need on Lonza Group Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Lonza Group Ltd Strategy Report
- Understand Lonza Group Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Lonza Group Ltd (Lonza) is a contract manufacturing and development solutions company. It offers services including commercial mammalian and microbial manufacturing, clinical development, and manufacturing. It also offers high-potential active pharmaceutical ingredients, cell and gene therapy capabilities, advanced intermediates, oral drug product development services, cell-culture modeling, genome editing, endotoxin products, and research media and testing products. Lonza provides solutions for health and well-being, microbial and hygiene control, and composites and material protection. Lonza serves biotechnology, pharmaceutical, academic, and government research industries; manufacturers of health and consumer products; formulators and service companies. The company operates manufacturing and R&D facilities in Asia, Europe, and the Americas. Lonza is headquartered in Basel, Switzerland.
Headquarters
Switzerland
Address
Muenchensteinerstrasse 38, Basel, 4002
Website
www.lonza.com
Telephone
41 61 3168111
No of Employees
18,000
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
LONN (SWF)
Revenue (2022)
$7.5B
7.9%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-46.2%
(2022 vs 2021)
Market Cap*
$43.6B
Net Profit Margin (2022)
XYZ
-50.1%
(2022 vs 2021)
* As of and is in US$
Lonza Group Ltd premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Biologics: | Development Technologies | - |
| Mammalian | GS Xceed Gene Expression System | Aldo |
| Microbial | XS Technologies for Microbial Expression | Biovert |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In April, the company entered into a collaboration agreement with Acumen Pharmaceuticals to manufacture sabirnetug (ACU193) for clinical development and commercialization. |
| 2024 | Contracts/Agreements | In March, the company entered into an agreement to acquire the Genentech manufacturing facility in Vacaville from Roche for US$1.2 billion. |
| 2024 | Contracts/Agreements | In March, the company entered into a collaboration with FDX Fluid Dynamix (FDX) and Fraunhofer Institute for Production Systems and Design Technology IPK to increase the development of messenger RNA (mRNA) based therapies. |
Competitor Comparison
| Key Parameters | Lonza Group Ltd | DSM-Firmenich AG | Dottikon ES Holding AG | Mabuhay Vinyl Corp | Actelion Pharmaceuticals Ltd |
|---|---|---|---|---|---|
| Headquarters | Switzerland | Switzerland | Switzerland | Philippines | Switzerland |
| City | Basel | Kaiseraugst | Dottikon | Makati | Allschwil |
| State/Province | - | - | - | - | Basel-Landschaft |
| No. of Employees | 18,000 | 29,301 | 694 | 153 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Albert M. Baehny | Chairman | Executive Board | 2018 | 71 |
| Philippe Deecke | Chief Financial Officer | Senior Management | 2021 | 51 |
| Caroline Barth | Chief Human Resources Officer | Senior Management | 2020 | 51 |
| Christoph Mader | Vice Chairman | Executive Board | 2020 | 64 |
| Maria Soler Nunez | Head - Operations | Senior Management | 2022 | 54 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward